These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29099667)

  • 1. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.
    Carretero G; Puig L; Carrascosa JM; Ferrándiz L; Ruiz-Villaverde R; de la Cueva P; Belinchon I; Vilarrasa E; Del Rio R; Sánchez-Carazo JL; López-Ferrer A; Peral F; Armesto S; Eiris N; Mitxelena J; Vilar-Alejo J; A Martin M; Soria C;
    J Dermatolog Treat; 2018 Jun; 29(4):334-346. PubMed ID: 29099667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 3. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U; Kragballe K; Reich K; Griffiths CE; Gu Y; Wang Y; Rozzo SJ
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition of treatment goals for moderate to severe psoriasis: a European consensus.
    Mrowietz U; Kragballe K; Reich K; Spuls P; Griffiths CE; Nast A; Franke J; Antoniou C; Arenberger P; Balieva F; Bylaite M; Correia O; Daudén E; Gisondi P; Iversen L; Kemény L; Lahfa M; Nijsten T; Rantanen T; Reich A; Rosenbach T; Segaert S; Smith C; Talme T; Volc-Platzer B; Yawalkar N
    Arch Dermatol Res; 2011 Jan; 303(1):1-10. PubMed ID: 20857129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
    Torii H; Sato N; Yoshinari T; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate Psoriasis: A Proposed Definition.
    Llamas-Velasco M; de la Cueva P; Notario J; Martínez-Pilar L; Martorell A; Moreno-Ramírez D
    Actas Dermosifiliogr; 2017 Dec; 108(10):911-917. PubMed ID: 28823420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
    Reich K; Griffiths CE
    Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PASI90 response: the new standard in therapeutic efficacy for psoriasis.
    Puig L
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):645-8. PubMed ID: 25370811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Daudén E; Puig L; Ferrándiz C; Sánchez-Carazo JL; Hernanz-Hermosa JM;
    J Eur Acad Dermatol Venereol; 2016 Mar; 30 Suppl 2():1-18. PubMed ID: 26812550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating to Target-A Realistic Goal in Psoriasis?
    Gordon KB; Armstrong AW; Menter MA; Wu JJ
    Semin Cutan Med Surg; 2018 Feb; 37(2S):S44-S47. PubMed ID: 29614137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical meaningfulness of complete skin clearance in psoriasis.
    Strober B; Papp KA; Lebwohl M; Reich K; Paul C; Blauvelt A; Gordon KB; Milmont CE; Viswanathan HN; Li J; Pinto L; Harrison DJ; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2016 Jul; 75(1):77-82.e7. PubMed ID: 27206759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
    Puig L; Bordas X; Carrascosa JM; Daudén E; Ferrándiz C; Hernanz JM; López-Estebaranz JL; Moreno JC; Sánchez-Carazo JL; Vanaclocha F; Vázquez-Veiga H;
    Actas Dermosifiliogr; 2009 May; 100(4):277-86. PubMed ID: 19463230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.